Linda Z. Penn

Affiliations: 
Medical Biophysics University of Toronto, Toronto, ON, Canada 
Area:
Molecular Biology, Pharmacy
Google:
"Linda Penn"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lin P, Lourenco C, Cruickshank J, et al. (2023) Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality. Cancer Research. OF1-OF15
Wei Y, Redel C, Ahlner A, et al. (2022) The MYC oncoprotein directly interacts with its chromatin cofactor PNUTS to recruit PP1 phosphatase. Nucleic Acids Research
Lourenco C, Resetca D, Redel C, et al. (2021) MYC protein interactors in gene transcription and cancer. Nature Reviews. Cancer
Longo J, van Leeuwen JE, Elbaz M, et al. (2020) Statins as anti-cancer agents in the era of precision medicine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Longo J, Pandyra AA, Stachura P, et al. (2020) Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Molecular Oncology
Longo J, Smirnov P, Li Z, et al. (2020) The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Leukemia
Longo J, Hamilton RJ, Masoomian M, et al. (2020) A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer and Prostatic Diseases
Hickman KA, Hariharan S, De Melo J, et al. (2019) Image-Based Analysis of Protein Stability. Cytometry. Part a : the Journal of the International Society For Analytical Cytology
Wei Y, Resetca D, Li Z, et al. (2019) Multiple direct interactions of TBP with the MYC oncoprotein. Nature Structural & Molecular Biology
Lourenco C, Kalkat M, Houlahan KE, et al. (2019) Modelling the MYC-driven normal-to-tumour switch in breast cancer. Disease Models & Mechanisms. 12
See more...